Adverse reactions in Table 2 and 3 are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000), including isolated reports. (See Tables 2 and 3.)


Additional adverse reactions observed during a 76-week prospective, open-label study in patients with dementia associated with Parkinson's disease treated with Exelon capsules: hypertension, hypotension (common).
The following additional adverse drug reactions have been reported in a clinical study in patients with dementia associated with Parkinson's disease treated with Exelon Patch: agitation, depression (common).
Additional adverse drug reactions which have been reported with Exelon Patch: Common: urinary incontinence.
Uncommon: cerebrovascular accident, delirium, psychomotor hyperactivity.
Rarely reported: erythema, urticaria, blister, dermatitis allergic.
Information from clinical trials in patients with dementia associated with Parkinson's disease: Table 4 lists the number and percentage of patients from the specific 24-week clinical study conducted with Exelon in patients with dementia associated with Parkinson's disease with pre-defined events that may reflect worsening of Parkinson's disease. (See Table 4.)

View ADR Monitoring Form